Role of EPAC in cAMP-Mediated Actions in Adrenocortical Cells

Aurélia E. Lewis1*, Reidun Aesoy2 and Marit Bakke2

1Department of Molecular Biology, University of Bergen, Bergen, Norway, 2Department of Biomedicine, University of Bergen, Bergen, Norway

Adrenocorticotropic hormone regulates adrenal steroidogenesis mainly via the intracellular signaling molecule cAMP. The effects of cAMP are principally relayed by activating protein kinase A (PKA) and the more recently discovered exchange proteins directly activated by cAMP 1 and 2 (EPAC1 and EPAC2). While the intracellular roles of PKA have been extensively studied in steroidogenic tissues, those of EPACs are only emerging. EPAC1 and EPAC2 are encoded by the genes RAPGEF3 and RAPGEF4, respectively. Whereas EPAC1 is ubiquitously expressed, the expression of EPAC2 is more restricted, and typically found in endocrine tissues. Alternative promoter usage of RAPGEF4 gives rise to three different isoforms of EPAC2 that vary in their N-termini (EPAC2A, EPAC2B, and EPAC2C) and that exhibit distinct expression patterns. EPAC2A is expressed in the brain and pancreas, EPAC2B in steroidogenic cells of the adrenal gland and testis, and EPAC2C has until now only been found in the liver. In this review, we discuss current knowledge on EPAC expression and function with focus on the known roles of EPAC in adrenal gland physiology.

Keywords: ACTH, steroidogenesis, cyclic AMP, EPAC, HPA axis, adrenal glands, adrenal cortex hormones

INTRODUCTION

In response to stress, the hypothalamic–pituitary–adrenal (HPA) axis is activated. Parvocellular neurons, located in the paraventricular nucleus of the hypothalamus release corticotrophin-releasing factor (CRF), which is transported to the anterior pituitary where it stimulates the corticotropes by binding to type I CRF receptors (1). In response to CRF, these cells release the prohormone pro-opiomelanocortin (POMC) (2). Through posttranscriptional modifications, the inert POMC is converted to biologically active peptides, including adrenocorticotropic hormone (ACTH) (3). ACTH enters the systemic circulation, binds to specific receptors located on the surface of adrenocortical cells, and stimulates the production of adrenocorticosteroid hormones, including cortisol, aldosterone, and adrenal androgens (4). Steroid hormones are produced from the same precursor, cholesterol, by a set of cytochrome P450 steroid hydroxylases (CYP11A1, CYP11B1 and CYP11B2, CYP17 and CYP21) and the steroid dehydrogenase 3βHSD (5). The enzymes are differentially expressed in the three zones of the adrenal cortex (zona glomerulosa, zona fasciculata, and zona reticularis) giving rise to zone-specific hormone production. In humans, the primary source of cholesterol for steroid hormone production is low density lipoprotein (LDL), which is imported via the LDL receptor (LDLR) from the blood stream. Once cholesterol enters the cell, hormone-sensitive lipase (HSL) converts it to free cholesterol substrate (6). Free cholesterol is then delivered to the inner mitochondrial membrane by the actions of steroidogenic acute regulatory protein (STAR) and cholesterol-binding proteins. CYP11A1 (or P450 cholesterol side chain cleavage)
catalyses the first and rate-limiting enzymatic step in the biosynthesis of all steroid hormones, the conversion of cholesterol to pregnenolone (7, 8). Pregnenolone can be further converted into different hormone intermediates in the endoplasmic reticulum and the final production of cortisol and aldosterone occurs in mitochondria within the zona fasciculata and zona glomerulosa, respectively (5).

In the adrenal cortex, ACTH coordinates the biosynthesis of steroid hormones via the second messenger cAMP. In response to ACTH binding to its receptor, conformational changes induce the release of G-proteins, which then activate membrane bound adenyl cyclases (ACs). Upon activation, ACs generates cAMP from ATP (Figure 1A). cAMP relays ACTH-mediated functions via EPAC and PKA (17, 20). The EPAC2A2 transcript might be specifically expressed in the brain, thyroid gland, proximal tubules of the kidney, ovary, and skeletal muscle express the highest levels of EPAC1, but lower levels of EPAC1 have been found in virtually all tissues examined, as well as in hematopoietic cells (15). Studies on murine tissues suggest that EPAC1, as well as EPAC2, mRNA expression is also regulated at different stages of development in embryos and after birth (16).

At the transcript level, four different isoforms arise from RAPGEF4, termed EPAC2A1, EPAC2A2, EPAC2B, and EPAC2C (Figure 1B) (17–20). The EPAC2A2 transcript might be specifically expressed in the brain (20), but the existence of a corresponding protein is yet to be demonstrated. Thus, potential biological roles for this isoform remain unknown. By contrast, the three other mRNAs are known to give rise to the proteins EPAC2A, EPAC2B, and EPAC2C. EPAC2A was the initial EPAC2 isoform identified (11), and is expressed predominantly in brain (with high levels in the cerebral cortex, hippocampus, habenua, cerebellum, and hypothalamus), pituitary, and endocrine pancreas (11, 17, 20). The EPAC2B isoform was identified by the group of Dr. Seino during their efforts in developing an EPAC2 knockout

**STRUCTURE AND FUNCTION OF EPAC ISOFORMS**

The identification of EPACs was reported in 1998 by two separate groups using different approaches. EPAC1 was discovered by de Rooij and colleagues in a database search for proteins containing cAMP-binding domains with the ultimate goal to explain the PKA-independent cAMP-induced activation of Rap1 (9). The same year, Kawasaki et al. identified both EPAC1 and EPAC2 in a screen for brain-specific genes with cAMP-binding motifs (11). In recent years, it has become evident that the EPAC proteins play essential roles in many biological processes, in some where EPAC and PKA collaborate to achieve a common biological response and in some where the two cAMP effectors have separate functions [reviewed in Ref. (12–14)].

**Expression of EPAC Isoforms**

The EPAC proteins are encoded by two different genes: RAPGEF3 (EPAC1) and RAPGEF4 (EPAC2), which both give rise to multiple transcripts. Three transcripts are produced from RAPGEF3, but only variant 1, encoding EPAC1, has been studied (13). EPAC1 is relatively ubiquitously expressed (9, 11). Specific parts of the brain, thyroid gland, proximal tubules of the kidney, ovary, and skeletal muscle express the highest levels of EPAC1, but lower levels of EPAC1 have been found in virtually all tissues examined, as well as in hematopoietic cells (15). Studies on murine tissues suggest that EPAC1, as well as EPAC2, mRNA expression is also regulated at different stages of development in embryos and after birth (16).

At the transcript level, four different isoforms arise from RAPGEF4, termed EPAC2A1, EPAC2A2, EPAC2B, and EPAC2C (Figure 1B) (17–20). The EPAC2A2 transcript might be specifically expressed in the brain (20), but the existence of a corresponding protein is yet to be demonstrated. Thus, potential biological roles for this isoform remain unknown. By contrast, the three other mRNAs are known to give rise to the proteins EPAC2A, EPAC2B, and EPAC2C. EPAC2A was the initial EPAC2 isoform identified (11), and is expressed predominantly in brain (with high levels in the cerebral cortex, hippocampus, habenua, cerebellum, and hypothalamus), pituitary, and endocrine pancreas (11, 17, 20). The EPAC2B isoform was identified by the group of Dr. Seino during their efforts in developing an EPAC2 knockout.
model (19). While confirming deletion of EPAC2A, they discovered the presence of a shorter transcript in the adrenal gland that lacked the N-terminal cAMP-binding domain ([19]; Figure 1B). Until now, EPAC2B expression has only been demonstrated in the adrenal gland (19–21), in the Leydig cell-derived cell line MA10 (21) and in endocrine pancreas (20). The physiological roles of EPAC2B appear to diverge from those of EPAC2A since EPAC2B is not able to substitute for EPAC2A in cellular assays monitoring insulin secretion (19). The shortest EPAC2 isoform, EPAC2C, was also identified by the group of Dr. Seino (17, 18) and has so far only been found in the liver, presumably solely in hepatocytes (18, 20). The strict tissue-specific expression of the different EPAC2 isoforms is controlled, at least in part, by DNA methylation. Detailed analyses of the EPAC2 gene have led to the identification of alternative promoters for the different isoforms (18, 20) and bisulfite sequencing demonstrated that the methylation status of the different promoters nearly perfectly mimics their activity and the expression pattern of the corresponding isoform (20).

Structure and Activation of EPAC Proteins

EPACs are multidomain proteins consisting of two main parts, i.e., an N-terminal regulatory region and a C-terminal catalytic region (Figure 1B). The regulatory region is built up by a CAMP-binding domain and a disheveled, Egl-10, pleckstrin (DEP) domain. EPAC2A contains two CAMP-binding domains, CAMP-A and CAMP-B, while EPAC1 has only one such domain. The domain structure of EPAC2B is similar to EPAC1 and lacks the first CAMP-A binding domain, while EPAC2C lacks both the CAMP-A and DEP domains (18, 19). The N-terminal CAMP-A domain in EPAC2B binds CAMP with low affinity and is not believed to be important for CAMP-induced activation (10). Instead, this domain appears to be important for the localization of EPAC2A near the plasma membrane (19). The DEP domain, by its ability to interact with phosphatidic acid, is also important in targeting EPAC to the plasma membrane upon activation by CAMP (22). The catalytic region consists of a CDC25 homology domain (CDC25HD) that catalyzes Rap1 activation, a Ras-exchange motif (REM) domain, and a Ras association (RA) domain (23). The regulatory regions of EPAC1 and EPAC2 function as inhibitors of the C-terminal GEF domain in the absence of CAMP. Binding of CAMP induces a conformational change that opens the catalytic CDC25HD domain from auto-inhibitory restraints and thereby permits GTP loading of Rap (10, 24–26). Both EPAC1 and EPAC2 contain potential RA domains, but only EPAC2 has been shown to interact with Ras-GTP, which contributes in recruiting EPAC2 to the plasma membrane. The enrichment of EPAC2 on the membrane through Ras binding is crucial for EPAC2-mediated Rap1 activation (27, 28). In addition to the plasma membrane, other subcellular localizations have been observed, such as the perinuclear region, nuclear membranes, and mitochondria for EPAC1 [reviewed in Ref. (29)] and the Golgi apparatus and the nucleus for EPAC2B (21).

Physiological Roles of EPAC

EPACs regulate a multitude of CAMP-mediated cellular processes in many different tissues [extensively reviewed in Ref. (23)], including the formation of cell–cell adhesion (24, 30–33), cell proliferation (34, 35), differentiation (36, 37), cell survival (38), ion channels regulation (39–41), and Ca2+-mediated signaling (23, 42, 43). The development of EPAC knockout mice models has led to a better insight into the biological functions of these proteins. In spite of the involvement of EPAC in multiple cellular pathways, mice lacking EPAC1, EPAC2, or both EPAC1 and EPAC2 do not show gross developmental or reproductive abnormalities. However recent studies have revealed that EPAC1−/− and EPAC2−/− mice display various phenotypes in response to stress or other challenges. For example, mice lacking EPAC1 or EPAC2 exhibit impaired glucose tolerance and dysfunctional insulin secretion after glucose challenge when compared with their wild-type littermates (44–46). Double knockout mice of both EPACs in the forebrain showed defects in long-term potentiation, spatial learning, and social interactions (47), whereas knocking out only EPAC2 is sufficient to induce social interactions impairment (48). Loss of EPAC2 also causes defects in memory retrieval in a fear conditioning paradigm (49). Interestingly, single nucleotide polymorphisms within the gene encoding EPAC2 have been linked to autism. Screening of 48 autistic individuals for mutations in the RAPGEF4 gene showed that four rare missense mutations may be a cause of autism (50). In spine synapses, these mutations alter the protein function of EPAC2 by affecting its Rap-GEF activity, the synaptic protein distribution and spine morphology (51). Activation of EPAC2 results in shrinkage of dendritic spine size as well as increased motility and turnover of the spines, thereby contributing to the plasticity of brain circuits (51, 52). Mice lacking EPAC1 or EPAC2 also present with phenotypes in the heart. Deletion of EPAC1 causes a mild decrease in basal cardiac functions, but more interestingly protects mice hearts from various stressors, such as arrhythmogenic stress (53). However, partly in contrast to this study, deletion of EPAC1 was reported to have no effect in cardiac function (54). Instead, loss of EPAC2 was shown to protect against β-adrenergic receptor-dependent arrhythmia (54). Most of the biological functions aforementioned have been attributed retrospectively to EPAC1 and EPAC2A due to their expression pattern. The roles of EPAC2B and EPAC2C, which were discovered later, are overall less studied. The potential roles of EPAC2B are discussed in chapter 2. In the liver, EPAC2C has been shown to suppress apoptosis and iNOS expression and activity in hepatocytes (55). EPAC2C may also control bile acid-stimulated canalicul formation in the liver (56).

EPAC IN THE HPA AXIS

EPAC2A is expressed in the hypothalamus and pituitary gland and EPAC2B in the adrenal gland. CAMP is known to be an essential regulator at all levels in the HPA axis (57) and, here, we review how EPAC2 is emerging to contribute to CAMP-mediated actions.

EPAC in the Hypothalamus and the Pituitary

In response to various stress factors, the expression of CRF is stimulated in the PVN of the hypothalamus. CRF synthesis is dependent in part upon the neuropeptide pituitary adenylyl
cyclosporin A (cAMP) and a subsequent elevation of cAMP (57, 58). So far, only PKA-dependent signaling has been reported to relay the stimulatory effect of cAMP on POMC expression. PKA inhibition was indeed shown to prevent binding of cAMP response element (CRE)-binding protein (CREB) on the CRE gene promoter and to inhibit transcriptional activation (59). EPAC has not been studied in PACAP-mediated actions in the PVN. However, EPAC was shown to mediate the effects of PACAP on long-term depression of synaptic transmission in the hippocampus through Rap in murine hippocampal slices (60), and in mice deleted for both Epac1 and Epac2 (47). These studies may, therefore, suggest a potential contribution of EPAC in PACAP-responsive PVN. In the suprachiasmatic nuclei of the hypothalamus, EPAC has been associated with leptin signaling (61) and the regulation of factors involved in setting circadian rhythms in Ref. (62). In noradrenergic neurons isolated from locus coeruleus (LC) in culture, EPAC, but not PKA, was shown to be involved in mediating the actions of cAMP (63). Thus, upon CRF binding to type-1 CRF receptor, LC neurons differentiate into norepinephrine-producing neurons via the activation of cAMP–EPAC–ERK/MAPK pathway, by potentiating brain-derived neurotrophic factor-stimulated synaptic plasticity via tyrosine kinase B signaling (63). Since LC neurons innervate PVN neurons, EPAC may, hence, indirectly stimulate the secretion of CRF from the hypothalamus [reviewed in Ref. (64)].

EPAC2A is also the dominant isoform expressed in the pituitary (19), but we still have very limited information about the potential roles of EPAC2 in this gland. Experiments in AtT20 pituitary cells demonstrated that EPAC, presumably EPAC2A, acts as a mediator of CRF1-induced signaling in corticotropes (65) and in HEK-293 overexpressing CRH-R2β cells (66). Upon activation of the CRH receptor, EPAC2A is involved in cAMP-mediated induction of ERK signaling (65), a pathway previously reported to induce POMC transcription in a PKA-independent manner (67). In addition, CRF receptor activation via Gq is known to signal to phospholipase C (PLC) and, hence, inositol (1,4,5) triphosphate (IP3) to induce calcium stores mobilization that contributes to ACTH secretion (1, 2, 68). Considering that the activation of PLC by EPAC–Rap2 has been reported to activate Ca2+ release and the secretion of hormones in different tissues (23), EPAC may also contribute to the secretion of ACTH in corticotropes.

**EPAC in Adrenal Physiology**

**Role of EPAC versus PKA in Steroidogenesis**

In the adrenal cortex, PKA is undoubtedly the major mediator by which cAMP regulates steroidogenesis (69–71). Once PKA is activated, both an acute and a chronic response occur, which contribute to increased steroid hormone synthesis. During the acute response, PKA phosphorylates HSL, which converts cholesterol esters to free cholesterol. This rapid response also involves an increase in StAR, which facilitates the movement of cholesterol to the inner mitochondrial membrane where the rate-limiting enzyme CYP11A1 resides (72). The chronic response corresponds to the transcriptional activation of all the other steroidogenic enzymes (73, 74). In a study by Schimmer et al., using microarray technology to investigate the effects of ACTH in mouse adrenal Y1 cells, the involvement of PKA was shown to account for up to 60% of the effects of ACTH on transcription, while only 6% could be assigned to PKC (70). This study clearly validated the dominant role of PKA in steroidogenesis, but left about 34% of the ACTH effects to be independent of PKA and PKC. In addition, another study had pointed to the importance of cAMP signaling, mediated independently of PKA, for aldosterone production in the adrenal zona glomerulosa (75). These findings suggest a role for EPAC in the regulation of adrenal function. The specific expression of the EPAC2B isoform in steroidogenic cells (19, 21) also points to roles for EPAC-dependent signaling in these cells. We, therefore, systematically assessed the involvement of PKA versus EPAC in steroidogenesis using cell permeable cAMP analogs specific for PKA and EPAC1/2 (N6-benzoyl-cAMP and 8-p-chlorophenylthio-2-O-methyl-cAMP) in adrenocortical cell lines (21). Our study demonstrated that PKA, and not EPAC2B, is the essential cAMP-induced regulator of factors involved in steroid hormone production (such as StAR, CYP11A1, and CYP17) as well as for the biosynthesis of cortisol and aldosterone. The role of EPAC2 was also studied in bovine zona fasciculata, expressing high levels of EPAC2 mRNA (76), using the same EPAC-specific cAMP analog (77). Although this analog induced cortisol biosynthesis, a non-hydrolyzable EPAC activator had no effect. The study concluded that metabolites of the hydrolyzable EPAC-specific analog induced the increase in cortisol observed in a cAMP-independent manner. Although seemingly opposite results were obtained with the same EPAC activating compound, these two studies indicate that EPAC is not important for cortisol production. cAMP rapidly induces the transcription factor nerve growth factor-induced clone B (NGFI-B), a regulator of several steroid hydroxylase genes (78–80). In adrenocortical cells in culture, we also found that NGFI-B-induction by cAMP is mediated by PKA and not by EPAC (21). Current investigations on HPA axis regulation in mouse knockout models will provide insights into the potential roles for EPAC1/2 in this neuroendocrine system.

**EPAC2B Contributes to Cytoskeletal Remodeling in the Adrenal Cortex**

In adrenocortical cells in culture, cAMP characteristically induces changes in cell shape and a concomitant reorganization of F-actin microfilaments [reviewed in Ref. (81)]. Furthermore, cytoskeletal reorganization has been shown to contribute to steroidogenic hormone production by allowing the correct positioning of lipid droplets, the ER and mitochondria where cholesterol and its metabolites are transported and metabolized (82–84). While using PKA- and EPAC-specific agonists to study their effect on steroidogenesis in adrenocortical cell lines, we observed that the activation of both cAMP effectors contributed to cell rounding and the reorganization of F-actin fibers (21). Considering that PKA activation contributes to the regulation and expression of many enzymes necessary for steroidogenesis, the additional effect mediated by PKA on F-actin remodeling would, hence, correlate well with enzymatic outputs. By contrast, the effects of EPAC on F-actin remodeling are not correlated to steroidogenesis and may, therefore, contribute to other aspects of adrenal physiology. In
line with this, we also found that activation of EPAC2B induced a marked decrease in migration (21). This finding implies that EPAC2B plays a role in cell motility and this suggests wider implications, such as adrenal cancer cell invasion. Although EPAC2 has so far not been implicated in cancer development, several studies have demonstrated roles, albeit contradictory, for EPAC1 in cell migration and metastasis (85). The molecular mechanisms implicated include, at least, an increase of Ca2+ release mediated by PLC-IP3 promoting actin remodelling and cell migration of melanoma cells (86) as well as integrin activation important for cell migration and metastasis of pancreatic cancer cells (87). EPAC2B may, hence, act in the same way as EPAC1 in the adrenal gland.

CONCLUSION

Since the discovery of EPACs in 1998, our understanding of cAMP-induced signaling and its roles in physiological processes has changed dramatically. Important initial in vitro studies on EPAC paved the way for current phenotypic analyses of genetic mouse models lacking EPAC in single or double knockouts. Based on these gene knockout models an important picture has emerged, namely that although deletion of EPAC does not cause gross defects in mice kept at standard protected conditions in the animal facility, exposure to stressful situations provoke significant phenotypes. EPAC2 is expressed along the HPA axis, and it is interesting to note that whereas the hypothalamus and pituitary specifically express EPAC2A, the adrenal cortex expresses solely the EPAC2B isoform. While EPAC has been shown to mediate potential roles in the hypothalamus, putative functions in the PVN are yet to be determined. At the hypophysyal level, EPAC2A has been implicated in the regulation of POMC expression, and in the adrenal cortex, EPAC2B affects the migration of adrenocortical cells in culture. The generation of spatial and temporal conditional gene knockout models is now required to pinpoint the specific roles of the different EPAC isoforms during development and adult life. Moreover, the ongoing efforts to develop isoform-specific agonists and antagonists hold great promise for insights into isoform-specific functions. Such compounds will also be important potential new drugs to treat diseases in which EPAC plays a role. Several studies do indeed suggest that EPACs are promising drug targets (88), giving hope that small molecules targeting EPACs will serve as useful treatments in the future.

AUTHOR CONTRIBUTIONS

AEL, RA, and MB wrote parts of the manuscript. AL coordinated editing.

REFERENCES

1. Haugel RL, Risbrough V, Oakley RH, Olivarres-Reyes JA, Dautzenberg FM. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. *Ann N Y Acad Sci* (2009) 1179:120–43. doi:10.1111/j.1749-6632.2009.05011.x
2. Stojilkovic SS, Tabak J, Bertram R. Ion channels and signaling in the pituitary gland. *Endocr Rev* (2010) 31:845–915. doi:10.1210/er.2010-0005
3. Smith AI, Funder JW. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. *Endocr Rev* (1988) 9:159–79. doi:10.1201/edrv-9-1-159
4. Gallo-Payet N. Adrenal and extra-adrenal functions of ACTH. *J Mol Endocrinol* (2016). doi:10.1530/JME-15-0042
5. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. *Endocr Rev* (2004) 25:947–70. doi:10.1202/er.2003-0030
6. Kraemer FR, Shen WJ. Hormone-sensitive lipase: control of intracellular tri-(di-acylglycerol and cholesteryl ester hydrolysis. *J Lipid Res* (2002) 43:1585–94. doi:10.1194/jlr.R200009-JLR200
7. Ishimura K, Fujita H. Light and electron microscopic immunohistochemistry of the localization of adrenal steroidogenic enzymes. *Microsc Res Tech* (1997) 36:445–53. doi:10.1002/(SICI)1097-0029(19970315)36:6<445::AID-MRTE2-3.0.CO;2-H
8. Miller WL, Bose HS. Early steps in steroidogenesis: intracellular cholesterol trafficking. *J Lipid Res* (2011) 52:2111–35. doi:10.1194/jlr.R016675
9. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* (1998) 396:474–7. doi:10.1038/24884
10. de Rooij J, Rehmann H, van Triest M, Cool RH, Wittinghofer A, Bos JL. Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs. *J Biol Chem* (2000) 275:20829–36. doi:10.1074/jbc.M001113200
11. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, et al. A family of cAMP-binding proteins that directly activate Rap1. *Science* (1998) 282:2275–9. doi:10.1126/science.282.5397.2275
12. Almharqiq M, Mei FC, Cheng X. Cyclic AMP sensor EPAC proteins and energy homeostasis. *Trends Endocrinol Metab* (2014) 25:60–71. doi:10.1016/j.tem.2013.10.004
13. Banerjee U, Cheng X. Exchange protein directly activated by cAMP encoded by the mammalian rapgef3 gene: structure, function and therapeutics. *Gene* (2015) 570:157–67. doi:10.1016/j.gene.2015.06.063
14. Sugawara K, Shibasaki T, Takahashi H, Seino S. Structure and functional roles of Epac2 (Rapgef4). *Gene* (2016) 575:577–83. doi:10.1016/j.gene.2015.09.029
15. Tiwari S, Fedelkis K, Moon EY, Flies A, Sherr DH, Lerner A. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis. *Blood* (2004) 103:2661–7. doi:10.1182/blood-2003-06-2154
16. Ulucan C, Wang X, Baljinnyam E, Bai Y, Okumura S, Sato M, et al. Developmental changes in gene expression of Epac and its upregulation in myoccardial hypertrophy. *Am J Physiol Heart Circ Physiol* (2007) 293:H1662–72. doi:10.1152/ajpheart.00159.2007
17. Otsaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. *Nat Cell Biol* (2000) 2:805–11. doi:10.1038/35041046
18. Ueno H, Shibasaki T, Iwanga T, Takahashi K, Yokoyama Y, Liu LM, et al. Characterization of the gene EPAC2: structure, chromosomal localization, tissue expression, and identification of the liver-specific isoform. *Genomics* (2001) 78:91–8. doi:10.1006/geno.2001.6641
19. Niumura M, Miki T, Shibasaki T, Fujimoto W, Iwanga T, Seino S. Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function. *J Cell Physiol* (2009) 219:652–62. doi:10.1002/jcp.21709
20. Hovik EA, Witsoe SL, Berghjem IR, Xu Y, Jakobsen I, Tengholm A, et al. DNA methylation of alternative promoters directs tissue specific expression of Epac2 isoforms. *PloS One* (2013) 8:e67925. doi:10.1371/journal.pone.0067925
21. Aumo L, Rusten M, Mellgren G, Bakke M, Lewis AE. Functional roles of protein kinase A (PKA) and exchange protein directly activated by 3',5'-cyclic adenosine 5'-monophosphate (cAMP) 2 (EPAC2) in cAMP-mediated actions in adrenocortical cells. *Endocrinology* (2010) 151:2151–61. doi:10.1210/en.2009-1139
22. Consonni SV, Gloerich M, Spanjaard E, Bos JL. cAMP regulates DEP domain-mediated binding of the guanine nucleotide exchange factor Epac1
to phosphatidic acid at the plasma membrane. *Proc Natl Acad Sci U S A* (2012) 109:3814–9. doi:10.1073/pnas.1117599109

23. Schmidt M, Dekker FJ, Maarsingh H. Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions. *Pharmacol Res* (2013) 65:670–709. doi:10.1012/

24. Rehmann H, Prakash B, Wolf E, Rueppel A, De Rooy J, Bos JL, et al. Structure and regulation of the cAMP-binding domains of Epac2. *Nat Struct Biol* (2003) 10:26–32. doi:10.1038/nsb878

25. Rehmann H, Arias-Palomo E, Hadders MA, Schwede F, Llorca O, Bos JL. Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B. *Nature* (2008) 455:124–7. doi:10.1038/nature07187

26. Rehmann H, Das J, Knipscheer P, Wittgenhofer A, Bos JL. Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state. *Nature* (2006) 439:625–8. doi:10.1038/nature04468

27. Li Y, Asuri S, Rehmann JF, Castro AF, Panaretivan C, Quilliam LA. The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP and Ras signals at the plasma membrane. *J Biol Chem* (2006) 281:2506–14. doi:10.1074/jbc.M508165200

28. Liu C, Takahashi M, Li Y, Song S, Dillon TJ, Shinde U, et al. Ras is required for the cyclic AMP-dependent activation of Rap1 via Epac2. *Mol Cell Biol* (2008) 28:7109–25. doi:10.1128/MCB.01060-08

29. Grandchamp M, Roscioni SS, Schmidt M. The role of Epac proteins, novel cyclic AMP mediators, in the regulation of immunity, immune and neuronal function. *Br J Pharmacol* (2010) 159:265–84. doi:10.1111/j.1476-5381.2009.00458.x

30. Rangarajan S, Ensink JM, Kuiper JB, de Rooij J, Price LS, Schwede F, et al. Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor. *J Biol Chem* (2003) 160:487–93. doi:10.1074/jbc.200209105

31. Bos JL. Epac: a new cAMP target and new avenues in cAMP research. *Nat Rev Mol Cell Biol* (2003) 4:733–8. doi:10.1038/nrm1197

32. Fukuhara S, Sakurai A, Sano H, Yamagishi A, Somekawa S, Takakura N, et al. Cyclic AMP mediators, in the regulation of immune, lung and neuronal function. *Sci Transl Med* (2011) 3:803–10. doi:10.1126/scitranslmed.3002618

33. Petersen RK, Madsen L, Pedersen LM, Hallenborg P, Hagland H, Viste K, et al. Cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions from hepatocyte apoptosis. *Mol Cell Biol* (2003) 23:1083–93. doi:10.1128/MCB.01060-03

34. Wang G, Chepurny OG, Malester B, Rindler MJ, Rehmann H, Bos JL, et al. AMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells. *J Physiol* (2006) 575:595–609. doi:10.1111/j.1469-7793.2006.57391

35. Morel E, Marcantonii A, Gastein M, Birkedal R, Rochais F, Garnier A, et al. cAMP-binding protein Epac induces cardiomyocyte hypertrophy. *Circ Res* (2005) 97:1296–304. doi:10.1161/01.RES.0000194325.31359.86

36. Shibasaki T, Takahashi H, Miki T, Sunaga Y, Matsumura K, Yanamaka M, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. *Proc Natl Acad Sci U S A* (2007) 104:19333–8. doi:10.1073/pnas.0707054104

37. Kai AK, Lam AK, Chen Y, Tai AC, Zhang X, Lai AK, et al. Exchange protein activated by cAMP (Epac)-deficient mice develop beta-cell dysfunction and metabolic syndrome. *FASEB J* (2013) 27:4122–35. doi:10.1096/fj.13-230433

38. Song WJ, Mondal P, Li Y, Lee SE, Hussain MA. Pancreatic beta-cell response to increased metabolic demand and to pharmacologic secretagogues requires EPAC2A. *Diabetes* (2013) 62:2796–807. doi:10.2337/db12-1394

39. Yang Y, Shu X, Liu D, Shang Y, Wu Y, Pei L, et al. Impairs learning and social interactions via aberrant regulation of miR-124 and Zif268 translation. *Neuron* (2012) 73:774–88. doi:10.1016/j.neuron.2012.02.003

40. Srivastava DP, Jones KA, Woolfrey KM, Burgdorf J, Russell TA, Kalmbach A, et al. Social, communication, and cortical structural impairments in Epac2-deficient mice. *J Neurosci* (2012) 32:11864–11878.

41. Ostroveanu A, van der Zee EA, Eisel UL, Schmidt M, Nijholt IM. Exchange protein activated by cyclic AMP 2 (Epac2) plays a specific and time-limited role in memory retrieval. *Hippocampus* (2010) 20:1018–26. doi:10.1002/hipo.20700

42. Bacchelli E, Blasi F, Biondolillo M, Lamb JA, Bonora E, Barnby G, et al. Screening of nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMPGEFII gene. *Mol Psychiatry* (2003) 8:916–24. doi:10.1038/sj.mp.4001340

43. Woolfrey KM, Srivastava DP, Photowala H, Yamashita M, Barsolina MV, Cahill ME, et al. Epac2 induces synapse remodeling and depression and its disease-associated forms alter spines. *Nat Neurosci* (2012) 15:1275–84. doi:10.1038/nn.2386

44. Penzes P, Woolfrey KM, Srivastava DP. Epac2-mediated dendritic spine remodeling: implications for disease. *Mol Cell Neurosci* (2011) 46:368–80. doi:10.1016/j.mcn.2010.11.008

45. Okumura S, Fujita T, Cai W, Jin M, Namekata I, Mototani Y, et al. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. *J Clin Invest* (2014) 124:2785–801. doi:10.1172/JCI64784

46. Pereira L, Cheng H, Lao DH, Na L, van Oort RJ, Brown JH, et al. Epac2 mediates cardiac beta-adrenergic-dependent sarcoplasmic reticulum Ca2+ leak and arrhythmia. *Circulation* (2013) 127:913–22. doi:10.1161/CIRCULATIONAHA.112.146819

47. Zhang B, Nweeze I, Lakshmanan I, Harbrecht BG. Activation of a cyclic AMP-guanine exchange factor in hepatocytes decreases nitric oxide synthase expression. *Shock* (2013) 39:70–6. doi:10.1097/SHK.0b013e3182760530

48. Fu D, Wakabayashi Y, Lippincott-Schwartz J, Arias IM. Bile acid stimulates hepatocyte polarization through a cAMP-Epac-MEK-LKB1-AMPK pathway. *Proc Natl Acad Sci U S A* (2011) 108:1403–8. doi:10.1073/pnas.1018376108

49. Kageyama K, Tamasawa N, Suda T. Signal transduction in the hypothalamic corticotropin-releasing factor system and its clinical implications. *Stress* (2011) 14:357–67. doi:10.3109/10253890.2010.536279

50. Kageyama K, Suda T. Regulatory mechanisms underlying corticotropin-releasing factor gene expression in the hypothalamus. *Endocr J* (2009) 56:335–44. doi:10.1507/endocrj.K09E-075

51. Agarwal A, Halvorson LM, Legradi G. Putative adenyly cyclase-activating polyacape (PACAP) mimics neuroendocrine and behavioral manifestations of stress: evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene. *Brain Res Mol Brain Res* (2005) 138:45–57. doi:10.1016/j.molbrain.2005.03.016

52. Steen I, de Rock F, Bertaso F, Abitbol K, Daniel H, Bockaert J, et al. Epac mediates PACAP-dependent long-term depression in the hippocampus. *J Physiol* (2009) 587:101–13. doi:10.1113/jphysiol.2008.157461

53. Fukuda M, Williams KW, Gautron L, Elmqist JK. Induction of leptin resistance by activation of cAMP-Epac signaling. *Cell Metab* (2011) 13:331–9. doi:10.1016/j.cmet.2011.01.016
Lewis et al.

EPAC in Adrenal Physiology

62. O’Neill JS, Maywood ES, Chesham JE, Takahashi JS, Hastings MH. cAMP-dependent signaling as a core component of the mammalian circadian pacemaker. Science (2007) 318:949–53. doi:10.1126/science.1152906

63. Traver S, Marien M, Martin E, Hirsch EC, Michel PP. The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticosterone releasing factor through the activation of a cAMP-dependent signaling pathway. Mol Pharmacol (2006) 70:30–40. doi:10.1124/mol.106.022715

64. Dunn AJ, Swiergiel AH. The role of corticosterone-releasing factor and noradrenaline in stress-related responses, and the inter-relationships between the two systems. Eur J Pharmacol (2008) 583:186–93. doi:10.1016/j.ejphar.2007.11.069

65. Van Kolen K, Dautzenberg FM, Verstraeten K, Royaux I, De Hoogt R, Gutknecht E, et al. Corticotropin releasing factor induced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2. Neuropharmacology (2010) 58:135–44. doi:10.1016/j.neuropharm.2009.06.022

66. Markovic D, Punn A, Lehner H, Grammatopoulos DK. Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration. Biochim Biophys Acta (2011) 1813:896–907. doi:10.1016/j.bbamcr.2011.02.005

67. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Gottfried LB, et al. Activation and induction of NUR77/NURR1 in corticosteroids by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol (2002) 16:1638–51. doi:10.1210/mend.16.7.0863

68. Gutknecht E, Van der Linden L, Van Kolen K, Verhoeven KE, Vauquelin G, Dautzenberg FM. Molecular mechanisms of corticosteroid-releasing factor receptor-induced calcium signaling. Mol Pharmacol (2009) 75:648–57. doi:10.1124/mol.109.050427

69. Clark BJ, Ranganath V, Combs R. Post-translational regulation of steroidogenic acute regulatory protein by cAMP-dependent protein kinase A. Endocr Res (2000) 26:681–9. doi:10.3109/07435800009048587

70. Schimmer BP, Cordova M, Cheng H, Tsoa A, Goryachev AB, Schimmer AD, et al. Global profiles of gene expression induced by adrenocorticotropic hormone in Y1 mouse adrenal cells. Endocrinology (2006) 147:2357–67. doi:10.1210/en.2005-1526

71. Aesoy R, Mellgren G, Morohashi K, Lund J. Activation of cAMP-dependent protein kinase increases the protein level of steroidogenic factor-1. Endocrinology (2002) 143:295–303. doi:10.1210/en.143.1.295

72. Stocco DM. The role of the STAR protein in steroidogenesis: challenges for the future. J Endocrinol (2000) 164:247–53. doi:10.1677/joe.0.164247

73. Sewer MB, Waterman MR. ACTH modulation of transcription factors responsible for steroid hydroxylase gene expression in the adrenal cortex. Micros Res Tech (2003) 61:300–7. doi:10.1002/jemt.10339

74. Sewer MB, Waterman MR. Adrenocorticotropic/cyclic adenosine 3′,5′-monophosphate-mediated transcription of the human CYP17 gene in the adrenal cortex is dependent on phosphatase activity. Endocrinology (2002) 143:1769–77. doi:10.1210/endo.143.5.8820

75. Gambaryan S, Butt E, Tas P, Smolenški A, Alloio B, Walter U. Regulation of aldosterone production from zona glomerulosa cells by ANG II and cAMP: evidence for PKA-independent activation of CaMK by cAMP. Am J Physiol Endocrinol Metab (2006) 290:E423–33. doi:10.1152/ajpendo.00128.2005

76. Liu H, Eneyart JA, Eneyart JJ. ACTH inhibits bTREK-1 K+ channels through multiple cAMP-dependent signaling pathways. J Gen Physiol (2008) 132:1–14. doi:10.1085/jgp.2007.151193

77. Eneyart JA, Eneyart JJ. Metabolites of an Epac-selective cAMP analog induce cortisol synthesis by adrenocortical cells through a cAMP-independent pathway. PLoS One (2009) 4:e6088. doi:10.1371/journal.pone.0006088

78. Bassett MH, Suzuki T, Sasano H, De Vries CJ, Jimenez PT, Carr BR, et al. The orphan nuclear receptor NGFI-B regulates transcription of 3beta-hydroxysteroid dehydrogenase: implications for the control of adrenal functional zonation. J Biol Chem (2004) 279:37622–30. doi:10.1074/jbc.M405431200

79. Wilson TE, Mow U, Weaver CA, Milbrandt J, Parker KL. The orphan nuclear receptor NGFI-B regulates expression of the gene encoding steroid 21-hydroxylase. Mol Cell Biol (1993) 13:861–8. doi:10.1128/MCB.13.2.861

80. Zhang P, Mellon SH. Multiple orphan nuclear receptors converge to regulate rat P450c17 gene transcription: novel mechanisms for orphan nuclear receptor action. Mol Endocrinol (1997) 11:891–904. doi:10.1210/mend.11.7.9940

81. Gallo-Payet N, Payet MD. Mechanism of action of ACTH: beyond cAMP. Microsc Res Tech (2003) 61:275–87. doi:10.1002/jemt.10337

82. Sewer MB, Li D. Regulation of steroid hormone biosynthesis by the cytoskeleton. Lipids (2008) 43:1109–15. doi:10.1007/s11745-008-3221-2

83. Sewer MB, Li D. Regulation of adrenocortical steroid hormone production by Rh0A-diaphanous 1 signaling and the cytoskeleton. Mol Cell Endocrinol (2013) 371:79–86. doi:10.1016/j.mce.2012.11.014

84. Issop I, Roné MB, Papadopoulos V. Organelle plasticity and interactions in cholesterol transport and steroid biosynthesis. Mol Cell Endocrinol (2013) 371:34–46. doi:10.1016/j.mce.2012.12.003

85. Almahairi M, Mei FC, Cheng X. The pleiotropic role of exchange protein directly activated by cAMP 1 (EPAC1) in cancer: implications for therapeutic intervention. Acta Biochim Biophys Sin (Shanghai) (2016) 48:75–81. doi:10.1093/abs/abs/gmv115

86. Baljinnyam E, De Lorenzo MS, Xie LH, Iwatsubo M, Chen S, Goydos JS, et al. Exchange protein directly activated by cAMP increases melanoma cell migration by a Ca2+–dependent mechanism. Cancer Res (2010) 70:5607–17. doi:10.1158/0008-5472.CAN-10-0056

87. Almahairi M, Chao C, Mei FC, Hellmich MR, Patrikeev I, Motamedi M, et al. Pharmacological inhibition and genetic knockdown of exchange protein directly activated by cAMP 1 reduce pancreatic cancer metastasis in vivo. Mol Pharmacol (2015) 87:142–9. doi:10.1124/mol.114.095158

88. Parnell E, Palmer TM, Yardwood SJ. The future of EPAC-targeted therapies: agonism versus antagonism. Trends Pharmacol Sci (2015) 36:203–14. doi:10.1016/j.tips.2015.02.003

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Lewis, Aesoy and Bakke. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.